Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 7
2.1 Robust Pipeline with Attempts to Meet Unmet Needs 7
2.2 Drugs Targeting Aß and Elements of Protein Misfolding Pathways Offer Potential New Therapies for the Treatment of AD and PD 7
2.3 Neurodegenerative Disease Pipeline Emphasizes Move Away from Conventional Areas towards Targets Related to Protein Misfolding and Neuroprotection 7
3 The Case for Innovation 9
3.1 Growing Opportunities for Biologic Products 10
3.2 Diversification of Molecular Targets 10
3.3 Innovative First-in-Class Product Development Remains Attractive 10
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 11
3.5 Sustained Innovation in Neurodegenerative Diseases 11
3.6 GBI Research Report Guidance 12
4 Clinical and Commercial Landscape 13
4.1 Therapy Area Overview 13
4.1.1 Alzheimer’s Disease 13
4.1.2 Parkinson’s Disease 14
4.1.3 Multiple Sclerosis 14
4.2 Disease Symptoms 14
4.3 Epidemiology 15
4.3.1 Alzheimer’s Disease 16
4.3.2 Parkinson’s Disease 16
4.3.3 Multiple Sclerosis 16
4.4 Etiology 17
4.4.1 Alzheimer’s Disease 17
4.4.2 Parkinson’s Disease 18
4.4.3 Multiple Sclerosis 18
4.5 Pathophysiology 19
4.5.1 Alzheimer’s Disease 19
4.5.2 Parkinson’s Disease 21
4.5.3 Multiple Sclerosis 23
4.5.4 Neurodegenerative Disease Area 24
4.6 Diagnosis 25
4.6.1 Alzheimer’s Disease 25
4.6.2 Parkinson’s Disease 25
4.6.3 Multiple Sclerosis 26
4.7 Comorbidities and Complications 26
4.8 Prognosis 27
4.8.1 Alzheimer’s Disease 27
4.8.2 Parkinson’s Disease 27
4.8.3 Multiple Sclerosis 28
4.9 Treatment Options 28
4.9.1 Alzheimer’s Disease 28
4.9.2 Parkinson’s Disease 29
4.9.3 Multiple Sclerosis 30
4.10 Overview of Marketed Products in Neurodegeneration 31
5 Assessment of Pipeline Product Innovation 33
5.1 Overview 33
5.2 Pipeline by Stage of Development and Molecule Type 33
5.2.1 Neurodegenerative Disease Overall 33
5.2.2 Key Neurodegenerative Disease Indications 34
5.3 Pipeline by Molecular Target 36
5.3.1 Neurodegenerative Disease Overall 36
5.3.2 Key Neurodegenerative Disease Indications 39
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 40
5.5 First-in-Class Programs Targeting Novel Molecular Targets 41
6 Signaling Network and Innovation Alignment within Neurodegenerative Disease 80
6.1 Complexity of Signaling Networks in Neurodegenerative Disease 80
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 80
6.3 First-in-Class Matrix Assessment 81
7 First-in-Class Target and Pipeline Program Evaluation 88
7.1 Pipeline Programs Targeting XXX 88
7.1.1 Pipeline Programs Targeting XXX 88
7.1.2 Pipeline Programs Targeting XXX 91
7.1.3 Pipeline Programs Targeting XXX 93
7.2 Pipeline Programs Targeting XXX 101
7.2.1 Pipeline Programs Targeting XXX 101
7.2.2 Pipeline Programs Targeting XXX 103
7.2.3 Pipeline Programs Targeting XXX 105
7.3 Pipeline Programs Targeting XXX 107
7.3.1 Pipeline Programs Targeting XXX 107
7.3.2 Pipeline Programs Targeting XXX 108
7.3.3 Pipeline Program Targeting XXX 110
7.4 Pipeline Programs Targeting XXX 111
7.4.1 Pipeline Programs Targeting XXX 111
7.4.2 Pipeline Programs Targeting XXX 113
7.5 Conclusion 114
8 Strategic Consolidations 115
8.1 Industry-Wide First-in-Class Deals 115
8.2 Licensing Deals 116
8.2.1 Deals by Region, Value and Year 116
8.2.2 Deals by Stage of Development and Value 117
8.2.3 Deals by Molecule Type, Molecular Target and Value 118
8.2.4 List of Deals with Disclosed Deal Values 119
8.3 Co-development Deals 122
8.3.1 Deals by Region, Value and Year 122
8.3.2 Deals by Stage of Development and Value 123
8.3.3 Deals by Molecule Type, Molecular Target and Value 123
8.3.4 List of Deals with Disclosed Deal Values 124
8.4 First-in-Class Programs with an without Prior Involvement in Licensing and Co-development Deals 127
9 Appendix 134
9.1 References 134
9.2 Abbreviations 146
9.3 Disease List 147
9.3.1 Alzheimer’s Disease 147
9.3.2 Parkinson’s Disease 147
9.3.3 Multiple Sclerosis 147
9.3.4 Other 147
9.4 Top 10 First-in-Class Targets for Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis 148
9.5 Research Methodology 150
9.5.1 Data integrity 150
9.5.2 Innovative and meaningful analytical techniques and frameworks: 150
9.5.3 Evidence based analysis and insight: 150
9.6 Secondary Research 150
9.6.1 Market Analysis 150
9.6.2 Pipeline Analysis 150
9.6.3 First-in-Class Matrix Assessment 151
9.6.4 First-in-Class Target Profiles 151
9.6.5 Licensing and Co-Development Deals 151
9.7 Contact Us 151
9.8 Disclaimer 151